Physician

Pathology

Dr. Marshall P. Goren, MD

Marshall Goren practices Pathology. Marshall Goren is a published doctor and has 27 publications published. The lastest was: 'Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.'

Publications

Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
Enhancement of methotrexate nephrotoxicity after cisplatin therapy.
Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children.
Two automated procedures for N-acetyl-beta-D-glucosaminidase determination evaluated for detection of drug-induced tubular nephrotoxicity.
Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein.
Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate.
Reduction of dimesna to mesna by the isolated perfused rat liver.
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
The stability of mesna in beverages and syrup for oral administration.
Oral mesna: a review.
Ifosfamide/mesna and hematuria.
Oral administration of mesna with ifosfamide.
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
False-positive ketone tests: a bedside measure of urinary mesna.
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
Ifosfamide in pediatric malignant solid tumors.
Mesna excretion and ifosfamide nephrotoxicity in children.
Cumulative renal tubular damage associated with cisplatin nephrotoxicity.
Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms'' tumor.
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.

Schools

University of Mi Med Sch

Doctors Specialties

Clinical Pathology
Pathology

Accepted Insurances

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Karin D. Berg, MD This Doctor is OpenDoctor Recommended.
	Dr. Terrence L. Geiger, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Gina A. Johnston, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard E. McLendon, MD This Doctor is OpenDoctor Recommended.
	Dr. Noel T. Florendo, MD This Doctor is OpenDoctor Recommended.
	Dr. A N. Sollee, MD
	Dr. Frank D. Osborn, MD This Doctor is OpenDoctor Recommended.
	Dr. Royce Joyner, MD This Doctor is OpenDoctor Recommended.
	Dr. Mondira Kundu, MD This Doctor is OpenDoctor Recommended.